CompletedNCT05486312

7-week Study With CT-155 in People With Schizophrenia

Device studyAges 18–64United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations: Culver City, United States · Garden Grove, United States and 8 more locationsSee all locations and recruitment
Activities: Device procedures described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: July 5, 2022

Recruitment status: Completed
Enrollment listed in the registry: 72
Sponsor: Click Therapeutics, Inc.
Sponsor type: Biotech company
Study type: Device
Intervention type: DEVICE
Study phase: Not clearly listed
Locations: United States
Age range: From 18 Years to 64 Years
Official registry ID: NCT05486312
Official title: Show the full official title
A Multi-center, Exploratory, Single-Arm, 7-week Study to Evaluate the Feasibility and Acceptability of Treatment With CT-155 in People With Schizophrenia

Completed

Culver City · Garden Grove · La Habra

7 more locations

FAQ

Who is behind this study?

The study sponsor is Click Therapeutics, Inc.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.